Advertisement

Topics

FDA Approves New Targeted Agent for Acute Myeloid Leukemia

12:57 EDT 1 Aug 2017 | Cancer Networks

The FDA has approved enasidenib (Idhifa) for the treatment of relapsed or refractory IDH2-mutant acute myeloid leukemia.

Original Article: FDA Approves New Targeted Agent for Acute Myeloid Leukemia

NEXT ARTICLE

More From BioPortfolio on "FDA Approves New Targeted Agent for Acute Myeloid Leukemia"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...